Understanding protection from SARS-CoV-2 by studying reinfection
J Overbaugh - Nature Medicine, 2020 - nature.com
Understanding protection from SARS-CoV-2 by studying reinfection | Nature Medicine Skip to
main content Thank you for visiting nature.com. You are using a browser version with limited …
main content Thank you for visiting nature.com. You are using a browser version with limited …
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific T cells and antibodies in coronavirus disease 2019 (COVID-19) protection: a prospective …
IA Molodtsov, E Kegeles, AN Mitin… - Clinical Infectious …, 2022 - academic.oup.com
Background During the ongoing coronavirus disease 2019 (COVID-19) pandemic, many
individuals were infected with and have cleared the virus, developing virus-specific …
individuals were infected with and have cleared the virus, developing virus-specific …
Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis
Background Randomised controlled trials of passive antibodies as treatment and
prophylaxis for COVID-19 have reported variable efficacy. However, the determinants of …
prophylaxis for COVID-19 have reported variable efficacy. However, the determinants of …
Impact of early SARS-CoV-2 antiviral therapy on disease progression
Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to
prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r …
prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r …
Covid-19 breakthrough infections in vaccinated health care workers
M Bergwerk, T Gonen, Y Lustig, S Amit… - … England Journal of …, 2021 - Mass Medical Soc
Background Despite the high efficacy of the BNT162b2 messenger RNA vaccine against
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough …